Premium
What's new in Guillain‐Barré syndrome in 2007–2008? *
Author(s) -
Van Doorn Pieter A.
Publication year - 2009
Publication title -
journal of the peripheral nervous system
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 67
eISSN - 1529-8027
pISSN - 1085-9489
DOI - 10.1111/j.1529-8027.2009.00215.x
Subject(s) - eculizumab , guillain barre syndrome , campylobacter jejuni , medicine , ganglioside , incidence (geometry) , randomized controlled trial , clinical trial , epidemiology , antibody , immunology , pediatrics , intensive care medicine , complement system , biology , bacteria , biochemistry , physics , optics , genetics
The years 2007 and early 2008 have been an exciting time for Guillain‐Barré syndrome (GBS) research. Epidemiological studies have shown that the incidence of GBS remains stable at about 2/100,000 per year but that there have been changes in hospitalization use, likely due to the widespread availability of IVIg. Research into mechanisms has shown the importance of single amino acids in Campylobacter jejuni and the importance of ganglioside conformation. In a murine model of anti‐ganglioside antibody‐mediated neuropathy, Eculizumab was effective in reversing clinical disease and preventing pathology. This suggests trials of Eculizumab in GBS should be considered. Unfortunately, there are no new randomized controlled trials in GBS to report although the unmet need is great.